California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
SAN MARINO, Calif. – July 10 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world’s first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers.